Developing tests to improve monitoring of low-risk prostate cancer patients
Official title: Biomarker Development Laboratory
Funded at Johns Hopkins University · NIH-10890725 · Data updated 2026-11-12
This study is looking to improve how we monitor low-risk prostate cancer by developing new tests that can help tell the difference between less serious and more aggressive forms of the disease, so that patients only get treatment when they really need it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 20, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $334,030 |
| NIH project number | 5U2CCA271895-02 |
| Project ID | NIH-10890725 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with low-risk prostate cancer who are eligible for active surveillance.
✕Less likely to help
Patients with aggressive prostate cancer or those who are not eligible for active surveillance may not benefit from this research.
What this research studies
This research focuses on creating advanced biomarker panels and diagnostic assays to enhance active surveillance for low-risk prostate cancer (PCa) patients. By analyzing serum, urine, and biopsy tissue, the project aims to distinguish between patients with low-risk and aggressive forms of cancer, thereby improving treatment decisions. The study will also work on non-invasive tests to detect early signs of disease progression, allowing for timely intervention. Patients will be monitored closely to ensure that only those who need treatment receive it, reducing unnecessary procedures.
Why it matters
Potential benefit: If successful, this research could lead to more accurate monitoring and treatment decisions for low-risk prostate cancer patients, minimizing overtreatment.
How similar studies have gone: Previous research has shown promise in developing biomarker panels for cancer detection, indicating that this approach has potential for success.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Zhang, Hui — Johns Hopkins University
- Study coordinator: Zhang, Hui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.